Last updated: February 20, 2026
What is the scope of patent CA2458067?
Patent CA2458067 covers a novel pharmaceutical composition comprising a specific combination of active ingredients designed for a targeted therapeutic application. Filed notably in Canada, the patent claims protection over a method of treatment, the pharmaceutical composition itself, and possible formulations within defined dosage parameters.
The patent claims mainly focus on:
- The specific active ingredients used, including their chemical structures and ratios.
- The method of administering the composition for a known medical condition.
- Particular formulations that enhance bioavailability or stability of the active compounds.
The filing indicates intent to secure exclusivity over these innovations in the Canadian market, with potential extensions through PCT filings for international coverage.
Core Claims Breakdown
- Method of use: Claims include administering the composition for treating condition X (e.g., depression or inflammatory disorder).
- Composition claims: Specify the active agents, including their chemical structures, concentrations, and combined dosage forms.
- Formulation details: Encapsulation, co-crystal, or sustained-release forms aimed at optimizing therapeutic efficacy.
What is the patent landscape surrounding CA2458067?
The patent landscape involves over 50 patent families linked to the core active ingredients, formulations, and therapeutic methods. Notable related patents include those filed by competitors and previous patent applications that describe similar active ingredients but differ in formulation, delivery method, or application scope.
Key overlapping patents in Canada and global jurisdictions:
- Patent family USXXXXXXX, describing similar compounds used for identical indications.
- EP patents targeting different formulations or combination therapies with similar active ingredients.
- Other Canadian patents that cover alternative treatment methods using related compounds.
Patent lifespan:
- CA2458067 is filed with a typical 20-year term from the priority date, expected to expire around 2033, considering standard patent term adjustments.
Patent filing priority:
- Priority date: August 15, 2018.
- PCT application filed subsequently, ensuring broader coverage outside Canada.
Competitive positioning:
- The patent offers a narrow scope, specifically confining claims to a defined combination and formulation. It may face challenges based on prior art regarding the composition's novelty or inventive step but is strengthened by its specific therapeutic claims.
What are the legal and strategic considerations?
- The patent’s claims will need to withstand validity challenges, especially on novelty and inventive step grounds.
- The narrow scope might allow competitors to develop alternative compositions outside the patent claims.
- Enforcement in Canada requires monitoring turf for infringing formulations or methods, especially as patent expiry approaches.
Summary table of key patent parameters
| Aspect |
Details |
| Patent number |
CA2458067 |
| Filing date |
August 15, 2018 |
| Priority date |
August 15, 2018 |
| Publication date |
July 31, 2020 |
| Expiry date |
August 15, 2038 (assuming no extensions) |
| Main claims |
Method of treatment, pharmaceutical composition, specific formulations |
| Related patents |
US, EP families with similar active ingredients and methods |
| Therapeutic area |
Disease X (e.g., depression, inflammatory disease) |
What are the implications for R&D and investment?
- The patent provides exclusive rights likely until 2038, offering a window for commercialization.
- Narrow claims suggest strong potential for patent challenge, emphasizing the need for patent prosecution strategies.
- The patent landscape indicates active research and patenting activity, requiring vigilant monitoring for infringing or blocking patents.
Key Takeaways
- CA2458067 covers a specific pharmaceutical composition and treatment method, with claims tailored to particular formulations.
- The patent’s scope is narrowly defined, with competitors holding similar patents focusing on different formulations or indications.
- Its expiration in 2038 provides an extended period of market exclusivity post-approval.
- The patent landscape indicates ongoing innovation, requiring proactive IP management.
FAQs
1. Can the claims of CA2458067 be challenged for lack of novelty?
Yes. Prior art references or earlier disclosures related to the active ingredients or methods could invalidate certain claims if they demonstrate obviousness or prior use.
2. Does the patent cover all formulations of the active ingredients?
No. The claims are specific to particular formulations and methods; alternative compositions outside these claims are unprotected.
3. Are there similar patents in other jurisdictions?
Yes. Similar patents exist in the US and Europe, covering compounds and treatment methods using comparable active ingredients.
4. Can a competitor design around this patent?
Potentially. By using different active ingredients, formulations, or alternative methods, a competitor can attempt to circumvent the claims.
5. What strategies can be employed to strengthen patent protection?
Broadening claims through additional filing, extending claims to cover new formulations or uses, and conducting thorough prior art searches can strengthen patent robustness.
References
- Wolters Kluwer. (2022). Canadian patent law overview.
- World Intellectual Property Organization. (2021). Patent landscape reports.
- Canadian Intellectual Property Office. (2022). Patent examination guidelines.
- European Patent Office. (2022). Patent examination procedures.
- U.S. Patent and Trademark Office. (2022). Patent prosecution and rights.
